Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Malik sold 3,500 shares of the company's stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $51.78, for a total transaction of $181,230.00. Following the sale, the executive vice president owned 153,902 shares in the company, valued at $7,969,045.56. The trade was a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Fady Ibraham Malik also recently made the following trade(s):
- On Tuesday, November 3rd, Fady Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $62.93, for a total transaction of $220,255.00.
- On Tuesday, October 20th, Fady Malik sold 3,500 shares of Cytokinetics stock. The stock was sold at an average price of $64.01, for a total transaction of $224,035.00.
- On Tuesday, October 6th, Fady Malik sold 3,500 shares of Cytokinetics stock. The stock was sold at an average price of $61.38, for a total transaction of $214,830.00.
- On Tuesday, September 22nd, Fady Malik sold 3,500 shares of Cytokinetics stock. The stock was sold at an average price of $68.29, for a total transaction of $239,015.00.
- On Tuesday, September 8th, Fady Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $75.46, for a total transaction of $264,110.00.
Cytokinetics Price Performance
Shares of CYTK traded down $0.33 during midday trading on Wednesday, reaching $51.32. The stock had a trading volume of 1,594,452 shares, compared to its average volume of 2,118,581. Cytokinetics, Incorporated has a 1-year low of $51.00 and a 1-year high of $88.31. The company's fifty day simple moving average is $63.25 and its two-hundred day simple moving average is $69.65. The company has a market cap of $7.15 billion, a price-to-earnings ratio of -8.50 and a beta of 0.45.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.06. The firm had revenue of $47.56 million for the quarter, compared to analysts' expectations of $41.88 million. Cytokinetics's revenue for the quarter was up 2356.5% on a year-over-year basis. During the same period last year, the firm posted ($2.55) earnings per share. On average, sell-side analysts forecast that Cytokinetics, Incorporated will post -5.85 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research firms have weighed in on CYTK. Leerink Partners cut their price target on Cytokinetics from $103.00 to $100.00 and set an "outperform" rating on the stock in a research note on Thursday, November 5th. William Blair began coverage on Cytokinetics in a research report on Friday, October 16th. They set an "outperform" rating for the company. HC Wainwright reiterated a "buy" rating and issued a $140.00 price objective on shares of Cytokinetics in a report on Monday, October 19th. Citizens Jmp raised their target price on Cytokinetics from $105.00 to $110.00 and gave the stock a "market outperform" rating in a research report on Friday, August 7th. Finally, Truist Financial boosted their target price on Cytokinetics from $106.00 to $112.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $106.67.
Check Out Our Latest Analysis on Cytokinetics
Hedge Funds Weigh In On Cytokinetics
Several hedge funds have recently made changes to their positions in the company. Pictet Asset Management Holding SA increased its position in shares of Cytokinetics by 18.4% during the third quarter. Pictet Asset Management Holding SA now owns 1,374,523 shares of the biopharmaceutical company's stock worth $90,569,000 after purchasing an additional 214,060 shares in the last quarter. GW&K Investment Management LLC lifted its holdings in shares of Cytokinetics by 11.1% in the 3rd quarter. GW&K Investment Management LLC now owns 1,017,714 shares of the biopharmaceutical company's stock valued at $67,078,000 after purchasing an additional 101,607 shares during the last quarter. Fisher Asset Management LLC boosted its position in shares of Cytokinetics by 10.1% in the 3rd quarter. Fisher Asset Management LLC now owns 818,832 shares of the biopharmaceutical company's stock valued at $53,969,000 after purchasing an additional 75,135 shares during the period. ADAR1 Capital Management LLC boosted its position in shares of Cytokinetics by 17.1% in the 1st quarter. ADAR1 Capital Management LLC now owns 632,556 shares of the biopharmaceutical company's stock valued at $41,692,000 after purchasing an additional 92,390 shares during the period. Finally, Candriam S.C.A. boosted its position in shares of Cytokinetics by 39.3% in the 3rd quarter. Candriam S.C.A. now owns 617,386 shares of the biopharmaceutical company's stock valued at $40,841,000 after purchasing an additional 174,320 shares during the period.
About Cytokinetics
(
Get Free Report)
Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company's work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cytokinetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytokinetics wasn't on the list.
While Cytokinetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.